Cytosin-Arabinosid
Liver Cancer (Locally Advanced or Metastatic)
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Liver Cancer (Locally Advanced or Metastatic) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Yttrium-90 Niek Wijnen | Phase 2 | B |
Giapreza Niek Wijnen | Phase 2 | CCC |
Autologous Immune Cells Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Phase 1/2 | CC |
Daunorubicin Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Phase 1/2 | CC |
sh009 Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →